Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

[Concentrations of antiangiogenic factors, triglycerides, glucose and insulin in women with two types of preeclampsia].

Kornacki J, Wirstlein P, Skrzypczak J.

Ginekol Pol. 2013 Sep;84(9):770-5. Polish.

PMID:
24191515
2.

Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.

Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, Dong Z, Than NG, Yeo L, Hernandez-Andrade E, Conde-Agudelo A, Hassan SS.

Am J Obstet Gynecol. 2013 Apr;208(4):287.e1-287.e15. doi: 10.1016/j.ajog.2013.01.016.

3.

The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes.

Holmes VA, Young IS, Patterson CC, Maresh MJ, Pearson DW, Walker JD, McCance DR; Diabetes and Preeclampsia Intervention Trial (DAPIT) Study Group..

Diabetes Care. 2013 Nov;36(11):3671-7. doi: 10.2337/dc13-0944.

4.

Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion.

Soto E, Romero R, Kusanovic JP, Ogge G, Hussein Y, Yeo L, Hassan SS, Kim CJ, Chaiworapongsa T.

J Matern Fetal Neonatal Med. 2012 May;25(5):498-507. doi: 10.3109/14767058.2011.591461.

5.

Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy.

Park HJ, Kim SH, Jung YW, Shim SS, Kim JY, Cho YK, Farina A, Zanello M, Lee KJ, Cha DH.

BMC Pregnancy Childbirth. 2014 Jan 20;14:35. doi: 10.1186/1471-2393-14-35.

6.

Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia.

Leaños-Miranda A, Campos-Galicia I, Ramírez-Valenzuela KL, Chinolla-Arellano ZL, Isordia-Salas I.

Hypertension. 2013 May;61(5):1118-25. doi: 10.1161/HYPERTENSIONAHA.111.00754.

7.

Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort.

Villa PM, Hämäläinen E, Mäki A, Räikkönen K, Pesonen AK, Taipale P, Kajantie E, Laivuori H.

BMC Pregnancy Childbirth. 2013 May 12;13:110. doi: 10.1186/1471-2393-13-110.

8.

[The role of angiogenic factors in preeclampsia].

Alasztics B, Gullai N, Molvarec A, Rigó J Jr.

Orv Hetil. 2014 Nov 23;155(47):1860-6. doi: 10.1556/OH.2014.30042. Review. Hungarian.

PMID:
25403279
9.

[Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].

Gao J, Shen J, Jiang Y, Zhou X, Qi H, Liu X, Liu J, Yang J, Bian X.

Zhonghua Fu Chan Ke Za Zhi. 2014 Jan;49(1):22-5. Chinese.

PMID:
24694913
10.

Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.

Vatten LJ, Åsvold BO, Eskild A.

Acta Obstet Gynecol Scand. 2012 Dec;91(12):1388-94. doi: 10.1111/j.1600-0412.2012.01516.x.

PMID:
22882089
11.

A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.

Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, Yeo L, Conde-Agudelo A, Hassan SS.

J Matern Fetal Neonatal Med. 2009 Nov;22(11):1021-38. doi: 10.3109/14767050902994754.

12.

Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.

Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ.

Circulation. 2010 Aug 3;122(5):478-87. doi: 10.1161/CIRCULATIONAHA.109.895458. Erratum in: Circulation. 2011 Sep 13;124(11):e302.

13.

Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.

Leaños-Miranda A, Campos-Galicia I, Isordia-Salas I, Rivera-Leaños R, Romero-Arauz JF, Ayala-Méndez JA, Ulloa-Aguirre A.

J Hypertens. 2012 Nov;30(11):2173-81. doi: 10.1097/HJH.0b013e328357c0c9.

PMID:
22902831
14.

The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia.

Pinheiro CC, Rayol P, Gozzani L, Reis LM, Zampieri G, Dias CB, Woronik V.

Prenat Diagn. 2014 Nov;34(11):1084-92. doi: 10.1002/pd.4432.

PMID:
24916790
15.

Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia.

Rana S, Hacker MR, Modest AM, Salahuddin S, Lim KH, Verlohren S, Perschel FH, Karumanchi SA.

Hypertension. 2012 Aug;60(2):451-8. doi: 10.1161/HYPERTENSIONAHA.112.195065.

16.

Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor.

Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Gonçalves LF, Medina L, Edwin S, Hassan S, Carstens M, Gonzalez R.

Am J Obstet Gynecol. 2007 Apr;196(4):326.e1-13. Erratum in: Am J Obstet Gynecol. 2007 Jun;196(6):614.

17.

Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia.

De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'anna R.

Acta Obstet Gynecol Scand. 2008;87(8):837-42. doi: 10.1080/00016340802253759.

PMID:
18607829
18.

Circulating angiogenic factors and the risk of preeclampsia.

Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA.

N Engl J Med. 2004 Feb 12;350(7):672-83.

19.
20.

Human chorionic gonadotropin, angiogenic factors, and preeclampsia risk: a nested case-control study.

Asvold BO, Eskild A, Vatten LJ.

Acta Obstet Gynecol Scand. 2014 May;93(5):454-62. doi: 10.1111/aogs.12363.

PMID:
24575980
Items per page

Supplemental Content

Support Center